Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patien ...

Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA ...

A delay in the FDA decision for NT-501 could leave those with macular telangiectasia (MacTel) without any form of treatment ...

Sponsored content Eye health is something many of us take for granted. But looking after our eyes is important for ...

MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...

HealthDay News — Socioeconomic factors are linked to an increased risk for age-related macular degeneration (AMD), according to a study published online July 1 in Health Data Science.

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 ...

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...

It's normal for your eyes to change as you age, but these four expert-approved tips can help improve your eye health.

Neuralink Corp., Elon Musk’s brain-computer venture, and rivals like Science Corp. are making strides in technology that ...

Belite Bio, Inc. ( NASDAQ: BLTE) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Tom Lin - Chairman and Chief Executive Officer Hendrik Scholl - Chief Medical Officer Nathan Mata - Chief ...